GTB 6550
Alternative Names: GTB-6550; HER2 TriKE™Latest Information Update: 23 Apr 2025
At a glance
- Originator GT Biopharma
- Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin 15 replacements; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Gastrointestinal cancer
Most Recent Events
- 23 Apr 2025 Preclinical development is ongoing USA for Gastrointestinal and Breast cancer (GT Biopharma pipeline, April 2025)
- 28 Jan 2025 No recent reports of development identified for preclinical development in Breast-cancer in USA (Parenteral)
- 28 Jan 2025 No recent reports of development identified for preclinical development in Gastrointestinal-cancer in USA (Parenteral)